[HTML][HTML] Tyrosine kinase inhibitors for the treatment of EGFR mutation-positive non–small-cell lung cancer: a clash of the generations
R Shah, JF Lester - Clinical lung cancer, 2020 - Elsevier
The availability of 3 generations of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) with different pharmacologic characteristics and clinical profiles has …
inhibitors (TKIs) with different pharmacologic characteristics and clinical profiles has …
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised …
K Park, EH Tan, K O'Byrne, L Zhang, M Boyer… - The Lancet …, 2016 - thelancet.com
Summary Background The irreversible ErbB family blocker afatinib and the reversible EGFR
tyrosine kinase inhibitor gefitinib are approved for first-line treatment of EGFR mutation …
tyrosine kinase inhibitor gefitinib are approved for first-line treatment of EGFR mutation …
Impact of EGFR inhibitor in non–small cell lung cancer on progression-free and overall survival: a meta-analysis
Background The epidermal growth factor receptor (EGFR) signaling pathway is crucial for
regulating tumorigenesis and cell survival and may be important in the development and …
regulating tumorigenesis and cell survival and may be important in the development and …
Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer
K Kaira, T Naito, T Takahashi, E Ayabe, R Shimoyama… - Lung Cancer, 2010 - Elsevier
PURPOSE: The use of erlotinib after gefitinib failure in patients with non-small cell lung
cancer (NSCLC) is not clearly clarified in clinical practice. We sought to compile the …
cancer (NSCLC) is not clearly clarified in clinical practice. We sought to compile the …
First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?
M Takeda, K Nakagawa - International journal of molecular sciences, 2019 - mdpi.com
Activating mutations of the epidermal growth factor receptor gene (EGFR) are a driving force
for some lung adenocarcinomas. Several randomized phase III studies have revealed that …
for some lung adenocarcinomas. Several randomized phase III studies have revealed that …
[HTML][HTML] Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients …
G Chen, J Feng, C Zhou, YL Wu, XQ Liu, C Wang… - Annals of …, 2013 - Elsevier
Background The OPTIMAL study found that erlotinib improved progression-free survival
(PFS) versus standard chemotherapy in Chinese patients with advanced EGFR mutation …
(PFS) versus standard chemotherapy in Chinese patients with advanced EGFR mutation …
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6) …
Background Afatinib—an oral irreversible ErbB family blocker—improves progression-free
survival compared with pemetrexed and cisplatin for first-line treatment of patients with …
survival compared with pemetrexed and cisplatin for first-line treatment of patients with …
[HTML][HTML] Patient-reported outcomes from FLAURA: osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer
NB Leighl, N Karaseva, K Nakagawa, BC Cho… - European Journal of …, 2020 - Elsevier
Background In the FLAURA trial, osimertinib demonstrated superior progression-free
survival and a favorable toxicity profile to erlotinib or gefitinib as initial therapy in patients …
survival and a favorable toxicity profile to erlotinib or gefitinib as initial therapy in patients …
[HTML][HTML] Examining treatment outcomes with Erlotinib in patients with advanced non–small cell lung cancer whose Tumors Harbor uncommon EGFR mutations
B Klughammer, W Brugger, F Cappuzzo… - Journal of Thoracic …, 2016 - Elsevier
Introduction Exon 19 deletions and the exon 21 L858R mutation of the epidermal growth
factor receptor gene (EGFR) predict activity of EGFR tyrosine kinase inhibitors, including …
factor receptor gene (EGFR) predict activity of EGFR tyrosine kinase inhibitors, including …
Clinical outcomes of afatinib versus osimertinib in patients with non-small cell lung cancer with uncommon EGFR mutations: a pooled analysis
C Wang, K Zhao, S Hu, W Dong, Y Gong, C Xie - The Oncologist, 2023 - academic.oup.com
Background The purpose of this analysis was to investigate the effectiveness of afatinib
compared to that of osimertinib in patients with non-small cell lung cancer (NSCLC) who …
compared to that of osimertinib in patients with non-small cell lung cancer (NSCLC) who …